iCAD (ICAD +2.3%) FDA) gains after saying it's received FDA clearance for its new cervical...

|By:, SA News Editor

iCAD (ICAD +2.3%) FDA) gains after saying it's received FDA clearance for its new cervical applicator for use with its Xoft Axxent Electronic Brachytherapy System to deliver high dose rate brachytherapy for intracavitary treatment of cancer of the uterus and cervix.